Experimental pill dramatically reduces 'bad' cholesterol

An experimental pill called enlicitide slashed levels of low-density lipoprotein (LDL) cholesterol, commonly known as "bad" cholesterol, by up to 60%, according to a new phase three clinical trial published in the New England Journal of Medicine. If approved by the Food and Drug Administration, this novel medication could help millions in the U.S. significantly reduce their risk of heart attacks and strokes.